PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Notes from the Field: Preliminary Results After Implementation of a Universal Treatment Program (Test and Start) for Persons Living with HIV Infection - Lesotho, October 2015-February 2017.

Abstract Lesotho, a small, mountainous country completely surrounded by the Republic of South Africa, has a population of approximately 2 million persons with an estimated gross national income of $1,280 per capita; 73% of the population resides in rural areas (1). Lesotho has a generalized human immunodeficiency virus (HIV) epidemic (2). In 2014, the prevalence of HIV infection among persons aged 15-49 years was 24.6%, with an incidence of 1.9 new infections per 100 person-years of exposure (3). As the leading cause of premature death, HIV/AIDS (acquired immunodeficiency syndrome) has contributed to Lesotho's reporting the shortest life expectancy at birth among 195 countries and territories (4). In 2015, antiretroviral therapy (ART) coverage among HIV-positive persons in Lesotho was estimated to be 42% (5). In April 2016, Lesotho became the first country in sub-Saharan Africa to adopt the World Health Organization (WHO) recommendations for universal initiation of antiretroviral therapy for all HIV-positive persons, regardless of CD4 count (known as the "Test and Start" program or approach), with nationwide implementation occurring in June 2016 (6,7). Before implementation of Test and Start, many persons living with HIV infection in Lesotho were not eligible to initiate treatment until their CD4 count was <500 cells/mm(3).
PMID
Related Publications

Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa.

Challenges in initiating antiretroviral therapy for all HIV-infected people regardless of CD4 cell count.

Current drivers and geographic patterns of HIV in Lesotho: implications for treatment and prevention in Sub-Saharan Africa.

Socioeconomic aspects of human immunodeficiency virus (HIV) infection in developing countries.

Clinical and behavioral characteristics of adults receiving medical care for HIV infection --- Medical Monitoring Project, United States, 2007.

Authors

Mayor MeshTerms

Health Plan Implementation

National Health Programs

Universal Coverage

Keywords
Journal Title mmwr. morbidity and mortality weekly report
Publication Year Start




PMID- 28771456
OWN - NLM
STAT- MEDLINE
DA  - 20170803
DCOM- 20170808
LR  - 20170808
IS  - 1545-861X (Electronic)
IS  - 0149-2195 (Linking)
VI  - 66
IP  - 30
DP  - 2017 Aug 04
TI  - Notes from the Field: Preliminary Results After Implementation of a Universal
      Treatment Program (Test and Start) for Persons Living with HIV Infection -
      Lesotho, October 2015-February 2017.
PG  - 813-814
LID - 10.15585/mmwr.mm6630a4 [doi]
AB  - Lesotho, a small, mountainous country completely surrounded by the Republic of
      South Africa, has a population of approximately 2 million persons with an
      estimated gross national income of $1,280 per capita; 73% of the population
      resides in rural areas (1). Lesotho has a generalized human immunodeficiency
      virus (HIV) epidemic (2). In 2014, the prevalence of HIV infection among persons 
      aged 15-49 years was 24.6%, with an incidence of 1.9 new infections per 100
      person-years of exposure (3). As the leading cause of premature death, HIV/AIDS
      (acquired immunodeficiency syndrome) has contributed to Lesotho's reporting the
      shortest life expectancy at birth among 195 countries and territories (4). In
      2015, antiretroviral therapy (ART) coverage among HIV-positive persons in Lesotho
      was estimated to be 42% (5). In April 2016, Lesotho became the first country in
      sub-Saharan Africa to adopt the World Health Organization (WHO) recommendations
      for universal initiation of antiretroviral therapy for all HIV-positive persons, 
      regardless of CD4 count (known as the "Test and Start" program or approach), with
      nationwide implementation occurring in June 2016 (6,7). Before implementation of 
      Test and Start, many persons living with HIV infection in Lesotho were not
      eligible to initiate treatment until their CD4 count was &lt;500 cells/mm3.
FAU - Schwitters, Amee M
AU  - Schwitters AM
AD  - Division of Global HIV and TB, Center for Global Health, CDC.
LA  - eng
PT  - Journal Article
DEP - 20170804
PL  - United States
TA  - MMWR Morb Mortal Wkly Rep
JT  - MMWR. Morbidity and mortality weekly report
JID - 7802429
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-HIV Agents/*therapeutic use
MH  - CD4 Lymphocyte Count
MH  - Female
MH  - HIV Infections/*drug therapy/epidemiology
MH  - *Health Plan Implementation
MH  - Humans
MH  - Incidence
MH  - Lesotho/epidemiology
MH  - Male
MH  - Middle Aged
MH  - *National Health Programs
MH  - Prevalence
MH  - Program Evaluation
MH  - *Universal Coverage
MH  - Young Adult
EDAT- 2017/08/05 06:00
MHDA- 2017/08/09 06:00
CRDT- 2017/08/04 06:00
AID - 10.15585/mmwr.mm6630a4 [doi]
PST - epublish
SO  - MMWR Morb Mortal Wkly Rep. 2017 Aug 4;66(30):813-814. doi:
      10.15585/mmwr.mm6630a4.